Europe Licensed Black Cohosh as a Menopause Medicine. American Guidelines Told Doctors Not to Bother.

The Oasis Health Journal · Submitted July 20, 2026 · 2:20 PM ET

Black cohosh is a woodland plant from the eastern United States. White flower spikes, feathery, taller than you. The part everybody wants is underground. It is one of the very few famous supplements that is actually American, which makes what happened next a little funny.

It moved to Europe and got a real job.

One root, three regulators, three answers

In the European Union, black cohosh is not a supplement. It is a licensed herbal medicine. The European Medicines Agency's Committee on Herbal Medicinal Products reviewed it and published a European Union herbal monograph concluding that black cohosh preparations can be used to treat menopausal complaints such as hot flushes and excessive sweating. It carries 'well-established use' status, which is the EU's way of saying the published evidence is strong enough to license the thing as a drug. The committee weighed around 20 clinical studies covering more than 6,000 patients who took it. The label rules are drug rules: adult women only, and do not go past six months without talking to a doctor.

In Australia, since 2007, every black cohosh product has to carry a warning that it may harm the liver in some individuals and should be used under the supervision of a healthcare professional.

In the United States it is a dietary supplement. No required warning. In its 2015 guidance on managing menopausal symptoms, the American College of Obstetricians and Gynecologists concluded that data do not show herbal supplements like black cohosh are efficacious for hot flashes and night sweats. The North American Menopause Society went further and advised clinicians against recommending it, because it is unlikely to be beneficial. They put 'unlikely' in italics. Nobody italicizes a word by accident.

Same plant. Same rhizome. Three regulators, three verdicts. That is not a botany problem. It is a paperwork problem, and the paperwork is the clinical trials.

The trials were never testing the same thing

In 2012 a Cochrane review pooled 16 randomized trials covering 2,027 women and concluded there was insufficient evidence to either support or oppose black cohosh for menopausal symptoms. Read the methods and you can see why. Daily doses ran from 8 mg to 160 mg. Trials ran from 8 weeks to 54 weeks. Some extracts were pulled with ethanol, some with isopropyl alcohol, and for some the original authors never said. A 2016 JAMA meta-analysis looked at four of those trials, 511 women, and also found nothing.

That is sixteen experiments on sixteen slightly different substances, averaged together, and the average came out to a shrug. Pool sixteen trials of coffee where the dose ranges from a thimble to a pot and some of it is decaf, and you get a shrug too.

The two most rigorous American failures both used ethanolic extracts. A 2006 trial gave 351 women 160 mg a day of a 70% ethanolic extract and found no difference from placebo at 3, 6, or 12 months. A 2009 trial gave 88 women 128 mg a day of a 75% ethanolic extract and got the same nothing. Meanwhile the extract carrying most of the European evidence, the one sold as Remifemin, is isopropanolic. Different solvent, different molecules coming out of the root.

Then the numbers moved

A 2023 pairwise meta-analysis in Menopause pooled 22 articles covering 2,310 women and found black cohosh extracts significantly better than placebo for overall menopausal symptoms (Hedges' g 0.575), for hot flashes (0.315), and for somatic complaints such as insomnia and fatigue (0.418). It did not beat placebo for anxiety or depression. Dropout rates matched placebo, which is a quiet way of saying people tolerated it.

Those are small to moderate effect sizes, and hot flashes were the weakest of the three. Nobody is claiming this replaces hormone therapy. But it is a different answer than the 2012 shrug, and the main thing that changed was which trials went into the pot.

A separate 2020 review in Climacteric restricted itself to the isopropanolic extract and reported consistent superiority over placebo. Worth knowing: that review's authors have ties to the extract's manufacturer. It is real published work and it is also not disinterested. Hold both facts at once.

Nobody knows what the active ingredient is

Here is the part that explains everything above. The compounds responsible for black cohosh's effects have not been identified. Not narrowed down. Not identified. The candidates include triterpene glycosides like actein and cimicifugoside, resins like cimicifugin, and aromatic acids like fukinolic acid. It is a lineup, not a suspect.

So the industry standardizes to a guess. Most products list at least 1 mg of triterpene glycosides per daily dose. Remifemin, the product behind a large share of the positive trials, is not standardized to triterpene glycosides at all. It is standardized to an isopropanolic extract equivalent to 40 mg of root and rhizome per daily dose. Two bottles can both say standardized and mean completely unrelated things.

Then it gets worse. When researchers ran DNA barcoding on 36 black cohosh supplements, 9 of them, a full quarter, were not Actaea racemosa. They were Asian Actaea species: A. cimicifuga, A. dahurica, A. simplex. Different plants, different chemistry, same label. A quarter of the shelf was a stranger.

About the liver

There are at least 83 reports worldwide of liver damage associated with black cohosh use, ranging from raised enzymes to liver failure. No causal relationship has been established, and some of those cases may trace back to exactly the species mix-up above, though nobody independently analyzed the implicated products to find out. Australia mandates the warning. The US Pharmacopeia recommended a caution label in 2008. The FDA does not require one. If you have a liver disorder, the US Pharmacopeia's advice is to skip it, and that is the easy call.

What this means at the shelf

If you are looking at black cohosh, the useful question is not whether black cohosh works. It is which extract, at what dose, from which species. That is a supply chain question wearing a botany costume, which is why it matters who made the bottle. Professional-grade lines get held to identity testing in a way the discount aisle does not.

It also turns up inside menopause support formulas and phytoestrogen blends, sharing a capsule with wild yam, dong quai, and evening primrose, one aisle over from chasteberry, which has its own separate and mostly premenstrual literature. Blends make the standardization question harder, not easier. Now you are guessing about four plants.

We source fresh per order instead of sitting on inventory. That means your box takes longer to arrive. It also means the bottle is not three years into its shelf life, which for a plant extract whose active compounds are still officially unidentified seems like the smaller risk to take.

Black cohosh spent a couple of centuries as an American plant that Europe took more seriously than we did. The trials are still arguing about it. The plant seems fine with that.

This article is for education only and is not medical advice. Talk with your own clinician before starting any supplement, especially if you have liver disease, are pregnant, or take prescription medication.

Sources

1. NIH Office of Dietary Supplements, Black Cohosh Fact Sheet for Health Professionals
2. European Medicines Agency, Cimicifugae rhizoma (black cohosh) herbal medicinal product summary and EU herbal monograph
3. Leach MJ, Moore V. Black cohosh (Cimicifuga spp.) for menopausal symptoms. Cochrane Database Syst Rev, 2012
4. Black cohosh extracts in women with menopausal symptoms: an updated pairwise meta-analysis. Menopause, July 2023
5. Review and meta-analysis: isopropanolic black cohosh extract iCR for menopausal symptoms, an update on the evidence. Climacteric, 2020
6. Franco OH et al. Use of plant-based therapies and menopausal symptoms: a systematic review and meta-analysis. JAMA, 2016
7. Baker DA et al. DNA barcode identification of black cohosh herbal dietary supplements. J AOAC Int, 2012
8. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society